Nin

Nin is an early-stage biotechnology company focused on the development of novel therapeutics targeting protein acetylation pathways. The company's primary research centers on N-terminal acetyltransferases (NATs), which are enzymes responsible for the most common protein modification in humans and are frequently dysregulated in various cancers. By developing selective inhibitors of these enzymes, Nin aims to create a new class of precision oncology treatments that can disrupt the stability and function of oncogenic proteins. The company is currently in the pre-clinical phase, conducting lead optimization and validation of its small molecule candidates.